AITRICS
AITRICS is a Seoul-based medical AI company that develops FDA-cleared clinical decision support software (VitalCare) using proprietary deep learning and a proprietary medical LLM (MOCA) to predict patient deterioration and sepsis in hospital settings, sold through direct enterprise sales to acute-care hospitals in Korea, the US, Malaysia and Vietnam.
- Company typePrivate
- Founded2016
- HeadquartersSeoul, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What AITRICS does
AITRICS (에이아이트릭스) is a Seoul-based medical AI company founded in 2016 that develops clinical decision support software for hospitals, with its flagship product AITRICS-VC (VitalCare) — an FDA 510(k)-cleared, Korean MFDS-approved, and Malaysia Class C-approved software that ingests structured EHR data including vital signs, blood tests, and 19 EMR data types to predict patient deterioration, sepsis, ICU transfer, cardiac arrest, and mortality 4–6 hours in advance. The technology stack consists of proprietary deep learning models trained on multi-institutional clinical datasets spanning 5–7 years, paired with the MAES (Multimodal AI Explanation System) framework that uses attention layers to deliver feature and time-importance explainability for clinicians, and the proprietary MOCA medical LLM that powers the broader V.Doc/V.Doc Pro product family.
The company sells through direct enterprise sales to hospital systems, generating revenue via multi-year subscription or per-bed licensing arrangements negotiated per hospital based on size, integration complexity, and deployment scope. Distribution is entirely direct (no channel partners identified) with dedicated Solution Engineers handling EHR integration, and demand generation is anchored on conference presence (HIMSS, KIMES, ERS, EUSEM, MEDICA), peer-reviewed publications, and tier-1 academic hospital validation partnerships. Operating geographies span Korea (HQ in Seoul's Yeoksam-dong, Gangnam-gu), the US (Virginia branch opened August 2024 alongside FDA clearance), Malaysia (Class C approval), and Vietnam (Department of Health MOU in Hung Yen Province, 2026), with additional market signals in Hong Kong, Japan, the UAE, and Denmark.
Target customers are acute-care hospitals and their Rapid Response Teams seeking to reduce sepsis mortality and missed deterioration events, served alongside medical-affairs research partnerships with academic medical centers including Seoul Asan Hospital, Yonsei Severance Hospital, Chung-Ang University Hospital, and Hallym University Chuncheon Sacred Heart Hospital. Financially, AITRICS has raised approximately $54M cumulatively across 2020, 2021, 2024 Series B (~27.1B KRW / $20.3M) and November 2025 Series C (~35B KRW / $23.8M, led by SV Investment Corp), and has scaled to 180+ employees with a recent office relocation to a larger Yeoksam station facility. Leadership comprises co-founder/CEO Kim Kwang-joon (김광준), co-founder/CRO Yang Eun-ho (양은호), co-founder Professor Yoo Jin-gyu (유진규), alongside a CFO, COO, CSO, CMO and CBO.
AITRICS firmographics
Firmographics- Name
- AITRICS
- Legal name
- 에이아이트릭스
- Website
- https://aitrics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AITRICS is a Seoul-based medical AI company that develops FDA-cleared clinical decision support software (VitalCare) using proprietary deep learning and a proprietary medical LLM (MOCA) to predict patient deterioration and sepsis in hospital settings, sold through direct enterprise sales to acute-care hospitals in Korea, the US, Malaysia and Vietnam.
- Ownership category
- akta.pro rank
AITRICS industry classification
Industry- Product category
- Clinical Decision Support Software
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Diagnostic & Triage Decision Support (HLACAGAA)
- akta.pro secondary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where AITRICS is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
AITRICS business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Software Licensing: AITRICS-VC is sold as a medical device software to hospitals. The company receives regulatory approval (Korean MFDS, US FDA, Malaysia MDA) and then licenses the software to healthcare institutions for integration with their EHR systems. Pricing is likely subscription or per-bed license model based on deployment scale.
- FDA-Cleared Software Distribution: Following FDA 510(k) clearance for AITRICS-VC, the company can commercialize the product in the US market. Revenue generated through direct hospital contracts and potential distributor partnerships.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise hospital deployment - Pricing based on hospital size and deployment scope |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
AITRICS product offering
Product offeringCore offering
AITRICS develops and sells FDA-cleared, Korea MFDS-approved, and Malaysia Class C-approved AI clinical decision support software for hospitals. Its flagship product, AITRICS-VC (VitalCare), ingests structured EHR time-series data (vital signs, labs, 19 types of EMR records) to predict patient deterioration, sepsis, ICU mortality, cardiac arrest, and unexpected ICU transfer hours in advance. The company also markets V.Doc, an AI symptom checker, and V.Doc Pro, a generative AI medical co-pilot for clinicians.
Product overview
AITRICS offers a unified medical AI platform anchored by VitalCare (AITRICS-VC), an FDA-cleared clinical decision support system that predicts patient deterioration, sepsis, and mortality. The product portfolio includes V.Doc (consumer-facing AI symptom checker), V.Doc Pro (medical co-pilot for healthcare professionals), and MOCA (proprietary medical LLM), all powered by the company's core AI technology for clinical decision support.
Differentiator
Problem solved
Functional benefit
Brands
- AITRICS-VC (VitalCare): AI-based medical device software for patient deterioration and sepsis prediction in hospital environments, providing clinical decision support integrated with hospital EHR systems.
- V.Doc
- V.Doc Pro
- MOCA
Products and services
- AITRICS-VC (VitalCare) Clinical decision support software that integrates with hospital EHR systems to predict patient deterioration, sepsis, mortality, cardiac arrest, and unexpected ICU transfer using deep learning models on vital signs, lab results, and 19 types of EMR data, with prediction horizons of 2-6 hours. Cleared by the US FDA (510(k)), Korea MFDS, and Malaysia Medical Device Authority (Class C). Targeted at acute care hospitals for use in general wards and ICUs.
- V.Doc
Quantifiable outcome
- Sepsis mortality reduced to approximately 10% with early prediction (within 1-3 hours of treatment initiation)
- +2 more outcomes
Companies that use AITRICS
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
AITRICS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
AITRICS partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- Department of Health of Hung Yen Province, VietnamminorMOU signed to explore AI adoption in healthcare, covering staff training, expert exchanges, and feasibility assessment in Vietnam's regulatory framework.
- Mayo Clinic PlatformcoreCollaboration with Mayo Clinic Platform for product development and validation. Series C funding announcement specifically mentions Mayo Clinic Platform collaboration for AI copilot development and clinical validation.
- Seoul Asan Hospital Research CentercoreMOU for joint research under the 'Research Hospital Cultivation Project' funded by Ministry of Health and Welfare. Focus on acute deterioration and severe patient diagnosis technology development and healthcare service innovation.
- Chung-Ang University HospitalcoreMOU for joint research on medical AI solutions, clinical studies, academic publications, national project collaboration, and new medical technology registration support.
- EunSung Medical Foundation (은성의료재단)coreSupply agreement for AITRICS-VC at Good Hospitals in Busan-Ulsan-Gyeongnam-Gyeongbuk region. Started with 3 hospitals (Good Culture, Good Samseon, Good Gang-an) with expansion plans to 11 facilities.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
AITRICS competitors and assessment
Company assessmentDirect peers
- Prenosis: Prenosis developed the FDA-authorized Sepsis ImmunoScore, an AI diagnostics tool for early sepsis detection using EHR and biomarker data. Direct peer in AI-driven sepsis risk prediction targeting hospital systems, with similar FDA-cleared clinical decision support positioning.
- Dascena: Dascena (Informerati) built machine-learning models for sepsis and deterioration prediction using EHR data. Direct peer in AI-driven inpatient deterioration prediction targeting hospital systems, with overlapping product functionality to AITRICS-VC.
- Etiometry: Etiometry provides FDA-cleared clinical decision support software for ICU patient monitoring and risk prediction. Direct peer in AI-based clinical decision support for acute/critical care settings with similar EHR-integrated deployment model.
- CLEW Medical: CLEW Medical offers AI-powered ICU analytics and early warning scores for clinical decision support. Direct peer in AI-driven patient deterioration prediction with similar enterprise hospital sales motion and FDA-cleared positioning.
- Cytovale: Cytovale developed IntelliSep, an FDA-cleared AI-enabled cellular biomarker diagnostic for sepsis. Direct peer in AI-driven sepsis diagnostics for hospital settings, addressing the same use case (early sepsis detection) from a different modality.
- Medical Informatics Corp (Sickbay): Medical Informatics Corp's Sickbay platform provides FDA-cleared patient monitoring and clinical decision support integrating waveforms and EHR data. Direct peer in FDA-cleared, EHR-integrated inpatient monitoring AI for hospitals.
Emerging players
- Inflammatix: Inflammatix develops host-response diagnostic tests augmented with AI for acute infection and sepsis triage. Comparable in targeting AI-enabled sepsis diagnostics for hospital use, but with a more diagnostics-oriented (sample-based) approach than AITRICS's EHR-based prediction.
Broad incumbents
- Philips (eICU/Patient Monitoring): Philips offers broad patient monitoring, tele-ICU, and clinical decision support capabilities within its connected care portfolio. Comparable as a broad incumbent with overlapping hospital patient deterioration and ICU monitoring functionality, but at much larger scale and broader product portfolio.
- GE HealthCare (Edison): GE HealthCare's Edison platform embeds AI-driven clinical decision support and patient monitoring into its hospital imaging and monitoring devices. Comparable as a broad incumbent operating in adjacent AI-enabled hospital decision support, with substantially larger distribution and customer footprint.
- Health Catalyst: Health Catalyst provides analytics and AI-driven decision support platforms for hospital systems, including care management and clinical improvement modules. Comparable as a broader healthcare data/AI platform for hospitals, though less specialized in real-time deterioration prediction than AITRICS.
Market position
Competitive moat5 records
Key risks6 records
Customer concentration
AITRICS social profiles
Digital presenceAITRICS compliance and trust
Trust signalCompliance2 records
AITRICS financial estimates
Financial estimateRevenue estimate
Valuation estimate
AITRICS leadership team
Management profileNumber of profiles
Profiles7 records
AITRICS funding detail
Funding detailFunding overview
Funding rounds5 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AITRICS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AITRICS
What does AITRICS do?
AITRICS develops and sells FDA-cleared, Korea MFDS-approved, and Malaysia Class C-approved AI clinical decision support software for hospitals. Its flagship product, AITRICS-VC (VitalCare), ingests structured EHR time-series data (vital signs, labs, 19 types of EMR records) to predict patient deterioration, sepsis, ICU mortality, cardiac arrest, and unexpected ICU transfer hours in advance. The company also markets V.Doc, an AI symptom checker, and V.Doc Pro, a generative AI medical co-pilot for clinicians.
Is AITRICS a public or private company?
AITRICS is a private company. It is classified as venture growth investor backed and is currently operating.
When was AITRICS founded?
AITRICS was founded in 2016. It employs 101 to 250 people.
Where is AITRICS based?
AITRICS is headquartered in Seoul, South Korea, in the Asia region.
How does AITRICS make money?
Two revenue lines are on record. Medical Device Software Licensing is the primary driver. The others are FDA-Cleared Software Distribution.
Who are AITRICS's main competitors?
Direct peers on record are Prenosis, Dascena, Etiometry, CLEW Medical, Cytovale and Medical Informatics Corp (Sickbay). Inflammatix is listed as an emerging player. Broad incumbents are Philips (eICU/Patient Monitoring), GE HealthCare (Edison) and Health Catalyst.
Does AITRICS have an API?
No public API is recorded for AITRICS.
What industry is AITRICS in?
AITRICS's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAA, Diagnostic & Triage Decision Support, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its SIC code is 7372.